Clinical Trial Update: Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 3 study evaluating amifostine in patients with Stage II/III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amifostine (amifostine)

Snippet

Sponsor: Radiation Therapy Oncology Group | Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer | Phase 3 | Status: COMPLETED